CJC-1295 / Ipamorelin: an evidence-first deep dive

This quiz is separate from the lesson so you can finish learning first, then test what you retained.

Lesson checkpoint

CJC-1295 / Ipamorelin: an evidence-first deep dive checkpoint

This checkpoint tests the lesson you just completed. Passing marks it complete and unlocks the next course step.

Get every question correct to pass.

1. Why is the name 'CJC-1295' especially important to clarify?

DAC and no-DAC products can have materially different pharmacokineticsAll CJC products are identicalThe name determines purityCJC-1295 is another name for ipamorelin

2. What did the classic CJC-1295 human study primarily establish?

Prolonged GH and IGF-1 pharmacodynamic effects in healthy adultsProven fat loss in obesityProven muscle gainA validated CJC/ipamorelin combination protocol

3. What did the early ipamorelin volunteer study show?

A dose-related acute GH-release response and short pharmacokinetic profileLong-term body-composition improvementSuperiority over tesamorelinA validated anti-ageing outcome

4. Why is combining two mechanistically complementary peptides not enough to prove the combination works?

The combination itself needs direct controlled evidence for the claimed outcomeMechanisms never matterTwo peptides cannot be studied togetherAny combination is automatically harmful

5. What is the key distinction between a hormone response and a clinical outcome?

A GH or IGF-1 change shows pathway engagement, not automatically muscle, fat, sleep or recovery benefitThey are always identicalHormone measurements are never usefulClinical outcomes only exist in animals

PThe Pep Report

Educational information only. Not medical advice.

Personalised Guide Safety & info Research Sourcing Guide